2015
DOI: 10.3109/08880018.2015.1071903
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic Biomarkers for Hodgkin Lymphoma

Abstract: The prognosis of patients with classical Hodgkin lymphoma following chemo- and radiotherapy has been excellent during the last 4 decades. However, the development of secondary malignancies is of major concern. Therefore, the reduction of radiotherapy application is a major objective of ongoing clinical trials. De-escalation of treatment may increase the risk of relapses and thus may lead to reappearance of prognostic factors. Prognostic biomarkers might help to identify patients who are at increased risk of re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 233 publications
(281 reference statements)
0
2
0
Order By: Relevance
“…We found several genes among the HL specific probe sets associated with HERV-like sequences with a known high expression in HL (Staege et al, 2008 , 2015 ; Hermes et al, 2016 ) such as the cancer/testis antigen PRAME (preferentially expressed antigen in melanoma), the cytokine EBI3 (Epstein-Barr virus induced 3), the chemokine fractalkine (CX3CL1), fascin (FSCN), or topoisomerase 2A (TOP2A). We also observed a high expression of all of these genes in HL cells in comparison to isolated B cells (Supplementary Figure 1 ).…”
Section: Resultsmentioning
confidence: 99%
“…We found several genes among the HL specific probe sets associated with HERV-like sequences with a known high expression in HL (Staege et al, 2008 , 2015 ; Hermes et al, 2016 ) such as the cancer/testis antigen PRAME (preferentially expressed antigen in melanoma), the cytokine EBI3 (Epstein-Barr virus induced 3), the chemokine fractalkine (CX3CL1), fascin (FSCN), or topoisomerase 2A (TOP2A). We also observed a high expression of all of these genes in HL cells in comparison to isolated B cells (Supplementary Figure 1 ).…”
Section: Resultsmentioning
confidence: 99%
“…Contemporary treatment of Hodgkin's lymphoma (HL) in children and adolescents is based on chemotherapy (CTx), and in some cases, on CTx combined with radiotherapy (RTx). A significant reduction of treatment is currently considered in cases without manifesting risk factors due to good results of HL treatment [1][2][3]. Adapted risk therapy strategy allows reducing toxicity, which is a major factor, contributing to a considerable decrease in the long-term quality of life and life expectancy in patients treated for HL in childhood [4].…”
Section: Introductionmentioning
confidence: 99%